Supplementary material BMJ Open

PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	и	Checklist item	Informatio	Line	
	#		Yes	No	number(s)
ADMINISTRATIVE IN	FORMA	TION			
Title					
Identification	1a	Identify the report as a protocol of a systematic review			1-3
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			NA
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			102-104
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			5-75
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			353-359
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			NA
Support					
Sources	5a	Indicate sources of financial or other support for the review			362-364
Sponsor	5b	Provide name for the review funder and/or sponsor			362-364
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			362-364
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known			112-145
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			146-151



1

2

Section/topic	#	Checklist item	Information reported		Line
			Yes	No	number(s)
METHODS				<i>*</i>	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review			162-186 Table 1
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage			187-192
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			195-197 Table 2
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review			204-207
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			208-219
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			220-224
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			225-237 Table 3
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			235-237 Table 3
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis			242-247
DATA					
	15a	Describe criteria under which study data will be quantitatively synthesized			248-258
Synthesis	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)			248-258
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)			259-265
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			248-258



Supplementary material BMJ Open

Section/topic	#	Checklist item	Information reported		Line
			Yes	No	number(s)
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)			259-261
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)			242-247

NA = not applicable



3